Expression of Ksp-cadherin during kidney development and in renal cell carcinoma by Thedieck, C et al.
Expression of Ksp-cadherin during kidney development and in
renal cell carcinoma
C Thedieck
1, M Kuczyk
2, K Klingel
3, I Steiert
1,C AM u ¨ller
1 and G Klein*,1
1Section for Transplantation Immunology and Immunohematology (ZMF), University Medical Clinic, Tu ¨bingen, Germany;
2Department of Urology,
University Medical Clinic, Tu ¨bingen, Germany;
3Department of Molecular Pathology, University Medical Clinic, Tu ¨bingen, Germany
Cadherins are a large family of cell–cell adhesion molecules acting in a homotypic, homophilic manner that play an important role in
the maintenance of tissue integrity. In the human kidney, several members of the cadherin family (including E- and N-cadherin,
cadherin-6, -8 and -11) are expressed in a controlled spatiotemporal pattern. Cadherin-16, also called kidney-specific (Ksp-) cadherin,
is exclusively expressed in epithelial cells of the adult kidney. In renal cell carcinomas (RCCs), which are considered to originate from
epithelial kidney tubular cells, a complex pattern of cadherin expression can be observed, but Ksp-cadherin expression has not been
analysed so far. In the present study, we show that the expression of Ksp-cadherin is completely abrogated in RCCs. Whereas Ksp-
cadherin can be detected at later stages of tubulogenesis during human renal development and in the distal tubules of adult kidneys,
no expression was found by immunohistochemistry or Western blot analysis in RCC tumour tissues and several RCC cell lines.
However, despite the lack of protein expression, mRNA synthesis of Ksp-cadherin could be detected by reverse transcriptase–
polymerase chain reaction analysis in all RCC tissues and most of the RCC cell lines studied, although at a reduced level. The loss of
Ksp-cadherin protein was only observed in the malignant part of the tumour kidneys, whereas in the normal part of the affected
kidneys Ksp-cadherin expression was clearly detected. These results indicate a downregulation of Ksp-cadherin in RCC and suggest a
role for this cell adhesion molecule in tumour suppression.
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The incidence of renal cell carcinoma (RCC) has increased steadily
during recent years and accounts today for 3% of all solid
malignancies (Mulders and De Mulder, 2002). Renal cell carcino-
mas are often associated with a poor prognosis due to early
metastasis which remains the predominant clinical problem for
therapeutical intervention in this type of cancer. Although several
new therapeutical modalities, for example, immunotherapy and
cytotherapy, have been developed over the years for metastatic
RCC patients, the prognosis, however, is still very pessimistic for
these patients (Oya and Murai, 2003). Dissemination of tumour
cells, which finally leads to clinically detectable metastases, is
certainly assisted by downregulation of cell adhesion molecules,
for example, members of the cadherin family.
Classical cadherins are a gene family of membrane-anchored cell
adhesion molecules which can be classified into two subfamilies,
namely type I (E-, N-, P- and R-cadherin) and type II (cadherin-5
to -12, -14 and -15) cadherins (Kemler, 1992; Nollet et al, 2000).
They are not only involved in Ca
2þ-mediated homophilic adhesive
cell–cell interactions, but also in transducing external signals into
the cells (Wheelock and Johnson, 2003). They are well known to
play important roles during embryonic development and in cell
differentiation, and also in the maintenance of adult tissue integrity.
Both type I and type II cadherins share a characteristic structure
consisting of five or more ectodomains, a transmembrane segment
and a conserved cytoplasmic tail which interacts via different
catenins with the cytoskeleton (Wheelock et al, 1996). However,
there are a few classical cadherins (which are not classified as type I
or type II) with a highly truncated cytoplasmic domain which
cannot interact with catenins. One of these cadherin molecules is
cadherin-16 also known as Ksp-cadherin (kidney specific) (Thom-
son et al, 1995; Igarashi, 2003). It is the only member of the
cadherin family that is exclusively found in the kidney. A kidney
epithelial cell-specific promoter is responsible for the restricted
expression pattern of Ksp-cadherin in renal tubular epithelial cells
(Whyte et al, 1999). In rabbit kidneys, Ksp-cadherin was found on
the basolateral membranes of both proximal and distal tubules, but
the most prominent expression pattern was seen on distal tubules
and collecting ducts (Thomson and Aronson, 1999).
E-cadherin expression is restricted to the distal tubules and
collecting ducts of the human kidney, whereas N-cadherin and
cadherin-6 expression are found on proximal tubules (Nouwen
et al, 1993; Paul et al, 1997). Cadherin-8 can only be detected on
developing tubular structures (Blaschke et al, 2002). This rather
complex pattern of cadherin expression in the normal adult kidney
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sis mirrored by cadherin expression in RCC (Tani et al, 1995;
Heicappell, 1999). More than 70% of all RCCs are clear cell
carcinomas that are thought to originate from proximal tubular
epithelial cells. Therefore, most of the analysed RCC cell lines
synthesised N-cadherin and cadherin-6 (Shimazui et al, 1996;
Blaschke et al, 2002). Expression of cadherin-6 can serve as a
prognostic marker for tumour progression (Shimazui et al, 2003,
2004; Paul et al, 2004). Some RCC cell lines also express E-cadherin
and cadherin-8 (Shimazui et al, 1996; Blaschke et al, 2002), but
since these cadherins are only found to be expressed on distal
tubules or during development, respectively, their expression in
the renal tumour cells must be regarded as an aberrant expression
pattern.
Although Ksp-cadherin is the only tissue-specific cadherin of
the kidney, its expression pattern in RCC has not been studied in
detail so far. To analyse Ksp-cadherin expression in the human
kidney, reverse transcriptase–polymerase chain reaction (RT–
PCR) analyses of embryonic kidney RNA and immunohistochem-
istry of embryonic and adult kidneys were performed. The mRNA
expression pattern in normal renal tissues and in tumour tissues
was compared by in situ hybridisation and by quantitative and
qualitative RT–PCR analyses. By immunohistochemistry and
Western blot analysis, the Ksp-cadherin protein expression of 11
RCC cell lines and of native tumour tissue was analysed and
compared to the expression within the normal part of the affected
kidneys, since alterations in the expression pattern of Ksp-
cadherin may be helpful for early diagnosis of RCC.
MATERIAL AND METHODS
Renal carcinoma cell lines and tissues
The following human RCC cell lines were obtained from ATCC
(Manassas, VA, USA): A-498 (HTB-44), Caki-2 (HTB-47), ACHN
(CRL-1611), 786-O (CRL-1932) and 796-P (CRL-1933). The RCC
cell lines MZ-1257, MZ-1774 and MZ-1851 were kindly provided by
Dr B Seliger (University of Mainz, Germany). Three other RCC cell
lines (TW-33, BN-30 and NH-99) were established in the
laboratory of Professor Gerhard Mu ¨ller (University of Go ¨ttingen,
Germany). All cell lines were grown in culture as described
recently (Blaschke et al, 2002).
Renal tissue samples were obtained at the time of surgery from
13 RCC patients and from three normal kidneys from the Urology
Departments of the Universities of Go ¨ttingen and Tu ¨bingen and
from the Protestant Hospital of Go ¨ttingen. Tissue samples were
snap frozen in liquid nitrogen and subsequently used for RT–PCR,
Western blot analysis or immunohistochemistry. The histology of
the tumour specimens is indicated in Table 1.
Reverse transcriptase–polymerase chain reaction
Total RNA was extracted from the RCC cell lines and from
different kidney tissues using the Trizol reagent (Gibco BRL,
Eggenstein, Germany). Isolated RNA was purified with RNeasy
columns (Qiagen, Hilden, Germany). RNA was further purified by
DNaseI digestion (Pharmacia, Freiburg, Germany). Total RNAs of
foetal kidneys from gestation weeks 6, 9 and 12 were commercially
available from ViroGen (Watertown, MA, USA).
Kidney-specific cadherin mRNA expression was analysed using
a two-step RT–PCR procedure. For cDNA synthesis, 1mg RNA was
transcribed with SuperScriptt First-Strand synthesis system
(Invitrogen, Karlsruhe, Germany). In total, 2ml of the obtained
cDNA were subjected to RT–PCR analysis using AmpliTAQ
polymerase (Roche Applied Biosystems, Mannheim, Germany).
cDNA quality was checked by PCR for detection of the house-
keeping gene b-actin. Primer sequences for b-actin were as follows:
b-actin (forward primer) 50-TCA GAA GGA TTC CTA TGT GGG C;
reverse primer 50-CCA TCA CGA TGC CAG TGG TA (product size
317bp). Primer sequences for Ksp-cadherin, designed according to
the sequence NM_004062 (GenBank) were as follows: forward 50-
CAA GTC ATG AGG TGG TGG TG, reverse 50-TCA TCT GTA TCC
TGG GCC TC (product size 358bp). cDNA samples were amplified
by 35 cycles at 941C for 40s (denaturation), 601C for 40s
(annealing) and 721C for 1min (elongation), followed by a final
elongation step at 721C for 10min. Each PCR analysis included
distilled water instead of cDNA as negative control. Polymerase
chain reaction products were sequenced by cycle sequencing in
both directions using the BigDye
s Terminator v3.1 Cycle
Sequencing kit (Roche Applied Biosystems) to control the
specificity of the assay.
Real-time PCR
For real-time PCR experiments, 1mg of RNA was reverse-
transcribed with iScriptt cDNA Synthesis Kit (BioRad, Munich,
Germany) according to the manufacturer’s instructions. Real-Time
PCR was performed with iQt SYBR
s Green Supermix (BioRad)
using the iCycler iQt Real-Time PCR Detection System (BioRad).
The b-actin and cadherin-16 primers described above were used at
a concentration of 20nM in a 25ml reaction volume. Reactions were
initially heated for 3min to 951C, then 40 cycles of 30s at 951C, 30s
at 601C and 20s at 721C were performed. After a final denaturation
step of 1min at 951C, a melting curve was recorded. Polymerase
chain reaction products were additionally analysed on a 2%
agarose gel.
Cadherin-16 mRNA was quantified in proportion to b-actin,
using the Gene Expression Macrot, version 1.1 (BioRad). The
expression levels were scaled relative to the sample with the lowest
expression level, which was designated a value of 1.
In situ hybridisation of kidney specimen
The Ksp-cadherin PCR product was cloned into the dual promotor
vector pCR
sII TOPO
s (Invitrogen) using the Invitrogen TOPO-
TA-cloning system. Correct sequence and the orientation of the
insert were determined by sequencing using M13 primers. The
plasmid was then linearised by complete digestion at the 50-end of
the inserted PCR-product with the NotI restriction enzyme
(Fermentas, St Leon-Rot, Germany). The obtained linearised
DNA was purified by chloroform/phenol extraction and served
subsequently as a template for preparation of single-stranded
35S-
labelled RNA probes, which were synthesised using SP6 RNA
polymerase. Enterovirus-specific single-stranded RNA probes were
used as negative controls (Klingel et al, 1992).
Frozen sections (5mm) were dried for 2h at 371C and fixed for
20min in 4% PFA at 41C. After washing with PBS, sections were
dehydrated in graded ethanol series (2 5min 70% ethanol,
Table 1 Analysed RCC tissue specimens
RCC no. Sex/age Histology
1 f/73a Clear cell carcinoma
2 m/58a Clear cell carcinoma
3 f/64a Clear cell carcinoma
4 f/85a Clear cell carcinoma
5 m/56a Clear cell carcinoma
6 f/71a Chromophil
7 m/55a Clear cell carcinoma
8 m/59a Clear cell carcinoma
9 m/54a Unknown
10 m/70a Clear cell carcinoma
11 f/68a Clear cell carcinoma
12 m/68a Clear cell carcinoma
13 f/66a Clear cell carcinoma
RCC¼renal cell carcinoma.
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s2 5min 100% ethanol). Until further use, sections could be
stored at  801C in 100% ethanol.
After rehydration in 100, 70 and 40% ethanol and finally in
distilled water, in situ hybridisation was performed as described
previously (Kandolf et al, 1987). In brief, slides were pretreated
with 0.2 M HCl, heated and digested with proteinase K. Then, the
slides were dehydrated in graded ethanol series, dried over night
and hybridised at 421C for 18h with 500ngml
 13 5 S-labelled RNA.
After washing, nonhybridised single-stranded RNA was digested
with RNase A as previously described (Klingel et al, 1992).
Hybridised preparations were autoradiographed with Kodak NBT2
film, exposed for several weeks, and stained with haematoxylin/
eosin.
Immunofluorescence staining and immunohistochemistry
of RCC cell lines and tissues
Renal cell carcinoma cell lines grown on chamber glass slides and
5mm cryostat sections of normal kidney tissues were fixed in
acetone for 10min at  201C. The fixed cells or tissues were
incubated with the anti-Ksp-cadherin antibody (clone 4H6/F9,
Zymed Laboratories, San Francisco, CA, USA) diluted 1:50 for 1h
at RT. After washing, a Cy3t-conjugated goat anti-mouse IgG
antibody (1:500, Dianova, Hamburg, Germany) was applied for
1h. For double immunofluorescence staining, the FITC-conjugated
lectin peanut agglutinin (PNA) (Linaris, Wertheim, Germany)
specific for distal renal tubules was employed. Cell nuclei were
identified by counterstaining with 40,6-diamidino-2-phenylindol-
dihydrochloride (DAPI; 1mgml
 1). Negative controls were per-
formed by omitting the primary antibody.
For immunohistochemistry, cryostat sections were stained for
Ksp-cadherin employing the Envision method (Dako, Hamburg,
Germany). In brief, sections were fixed with acetone and
endogenous peroxidase activity was blocked. Kidney specific-
cadherin antibody (diluted 1:50) was applied for 30min. After
washing, bound antibodies were detected by applying horseradish
peroxidase-labelled polymer conjugated to secondary anti-mouse
antibody. Peroxidase activity was visualised by addition of 3,30-
diaminobenzidine substrate solution. Slides were counterstained in
Mayer’s hemalum solution and mounted in Entellan embedding
medium (Merck, Darmstadt, Germany).
Paraffin-embedded foetal kidney tissues from 12th week’s
gestation were obtained from medically indicated abortions.
Paraffin sections were deparaffinised in xylene and rehydrated in
a graded ethanol series. Subsequently, the slides were heated three
times for 3min at 400W in a microwave oven in citrate buffer
(1mM sodium citrate, pH 6.0) to reverse crosslinking of the PFA
fixation. Then, the procedure was continued as described for the
immunohistochemical staining procedure.
Immunoblot analysis
Total protein extracts from the RCC cell lines and from different
kidney tissues were obtained by incubating cells or tissues for
60min on ice in extraction buffer containing 1% Triton-X-100, 1%
NP-40, 1mM CaCl2,1m M MgCl2, 150mM NaCl and 50mM Tris-HCl
pH 7.4. Solubilised proteins were separated on 10% polyacryla-
mide gels and transferred to nitrocellulose filters. Equal protein
loading was controlled by Ponceau S (0.1% wv
 1 in 1% vv
 1 acetic
acid) staining. Nonspecific protein-binding sites were blocked with
5% skimmed milk powder solution. The filters were probed with
the Ksp-cadherin antibody (diluted in 5% skimmed milk powder)
directed against the C-terminal part of the molecule. After
washing, bound cadherin antibodies were detected by alkaline
phosphatase-conjugated goat anti-mouse immunoglobulins
(Dako), followed by colorimetric reaction with the Fast-BCIP/
NBT system (Sigma, Taufkirchen, Germany).
Proteasome inhibiton assay
Renal cell carcinoma cell lines were seeded in six-well plates and
grown to 80% confluency, after which culture medium with 25 or
50mM N-Acetyl-Leucin-Leucin-Norleucin (ALLN, Merck Bios-
ciences, Schwalbach, Germany), which inhibits proteasome and
lysosome proteases, was added. After 4, 8 or 24h of incubation at
371C, 5% CO2 cells were washed thoroughly and lysed directly.
Cadherin-16 expression was analysed by subsequent Western Blot
analysis.
RESULTS
Kidney-specific cadherin in human foetal kidney
The expression pattern of Ksp-cadherin during different stages of
human kidney development was analysed using RNA of embryonic
kidneys of the 6th, 9th and 12th week of gestation. Reverse
transcriptase–PCR analyses revealed that Ksp-cadherin expression
could not be detected at the earliest stage analysed, but appeared in
the 9th week of gestation, increased during further development
Marker
6th week
9th week
12th week
Adult
A
B
nz
Figure 1 Expression of Ksp-cadherin in foetal kidney. (A) Kidney-specific
cadherin mRNA expression was studied by RT–PCR analysis with total
RNA derived from human embryonic kidneys at 6th, 9th and 12th week’s
gestation. Kidney-specific cadherin mRNA expression first arises in the 9th
week of pregnancy. (B) The micrograph shows an immunohistochemical
staining of Ksp-cadherin in embryonic human kidney (12th week of
gestation). Kidney-specific cadherin was detected in distal tubules and
collecting ducts (arrowheads), but not in the early nephrogenic zone (nz).
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sand was still present in the adult stage (Figure 1A). A control
amplification with b-actin-specific primers showed specific bands
of similar intensity, indicating that equal amounts of intact RNA of
all developmental stages were used (data not shown). As revealed
by immunohistochemistry, Ksp-cadherinþ cells in a 12th week’s
embryonic kidney were restricted to the more advanced distal
tubules and collecting ducts (Figure 1B). No staining signals were
found in the early nephrogenic zone where the transition of the
induced mesenchymal cells into the epithelial cells of comma- and
S-shaped bodies can be observed.
Kidney-specific cadherin in adult human renal distal
tubules
In the adult rabbit kidney, Ksp-cadherin expression was
detected on all parts of the renal tubules and collecting
ducts (Thomson and Aronson, 1999). In the same publication
it was reported (but not shown) that this ubiquitous renal
tubular expression pattern of Ksp-cadherin is well conserved in
human, mouse and rat kidneys. To unambiguously identify
the expression pattern in human kidneys, we labelled cryostat
sections of normal kidneys with a monoclonal antibody against
human Ksp-cadherin and counterstained them with a fluoro-
chrome-conjugated PNA lectin, which specifically recognises
epithelial cells of distal tubules and collecting ducts. Double
immunofluorescence staining revealed an expression of Ksp-
cadherin on distal tubules and collecting ducts, but no expre-
ssion was found on proximal tubules (Figure 2). Remarkably,
tubules with a strong PNA-lectin staining showed relatively weak
Ksp-cadherin expression and vice versa, suggesting that both
markers label different parts of the distal tubules with different
intensities.
PNA Cadherin-16 Merge
Figure 2 Expression of Ksp-cadherin in adult kidney. The micrographs show immunofluorescence staining with PNA lectin (PNA) and of Ksp-cadherin
(cadherin-16) in normal adult kidney tissue of RCC patient 11. The section was counterstained with DAPI to visualise the cell nuclei and the tubules (merge).
Ksp-cadherin is present in the tubules stained with PNA lectin, identifying them as distal tubules and collecting ducts, but not in proximal tubules.
Marker
A-498
Caki-2
CRL-1611
CRL-1932
CRL-1933
MZ-1257
MZ-1774
MZ-1851
TW-33
BN-30
NH-99
RCC
Normal
Ksp-cadherin
Figure 3 Detection of Ksp-cadherin mRNA expression in RCC cell lines and RCC tissues by RT–PCR analysis. Ksp-cadherin mRNA can be detected in
nearly all RCC cell lines except CRL-1611 and TW-33. In RCC and normal kidney tissues, Ksp-cadherin mRNA was also detected.
Marker
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Caki-2
CRL-1611
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250 kDa
150 kDa
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Figure 4 Analysis of Ksp-cadherin protein expression in RCC cell lines and RCC tissues by Western blotting. The Ksp-cadherin protein is only present in
the normal kidney, but not in any of the RCC cell lines or RCC tissues studied.
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To study Ksp-cadherin expression in RCC, 11 established RCC cell
lines were examined by RT–PCR and Western blot analyses. Nine
out of 11 RCC cell lines clearly synthesised Ksp-cadherin mRNA
(Figure 3). The identity of the 358bp amplification product, whose
sequence is located in exon 13 and exon 14 spanning parts of the
extracellular EC5 and EC6 domains of Ksp-cadherin, was verified
by cycle sequencing. However, by immunoblotting (Figure 4) and
immunofluorescence staining (data not shown), the Ksp-cadherin
protein could not be detected in any of the 11 analysed RCC cell
lines. To rule out the possibility that the Ksp-cadherin protein is
rapidly degraded by the proteasome, RCC cell lines were cultured
in the presence of 25 or 50mM of the proteasome inhibitor ALLN.
This treatment did not cause any change in the detection of Ksp-
cadherin by Western blot analysis (data not shown) arguing
against a proteasomal degradation of the Ksp-cadherin. The
expression of Ksp-cadherin mRNA and the absence of the intact
protein were also observed in RCC tissue, whereas in normal
kidney tissue the mRNA was present and a strong specific signal at
130kDa could be detected by immunoblotting, indicating that the
used anti-human Ksp-cadherin antibody is successfully applicable
for this method (Figures 3 and 4).
The discrepancy between the lack of Ksp-cadherin protein
expression but positive mRNA expression was partially solved by
quantitative real-time PCR with RNA from tumour tissues and the
corresponding nonaffected parts of the kidneys of four RCC
patients. It could be shown that the level of mRNA expression in
tumour tissues was 4–23 times lower in comparison to normal
tissues (Figure 5). By end point PCR after 40 cycles of
amplification, however, clear signals of amplified PCR products
were observed both in normal and tumour tissues (Figure 5).
To analyse mRNA expression of Ksp-cadherin directly in the
renal tissue, in situ hybridisation experiments with radioactively
labelled antisense RNA probes were performed. In the normal
kidney, strong signals of Ksp-cadherin mRNA expression could be
localised in distal tubules, whereas the signal intensity in proximal
tubules was not significantly above background (Figure 6A). In the
tumour tissues, which were analysed from 13 RCC patients, the
level of signal was not significantly higher than the background
labelling (Figure 6B), confirming a low level of Ksp-cadherin
mRNA.
The Ksp-cadherin protein expression pattern in 13 tumour
tissues and the corresponding normal parts of the kidneys, which
were available after total nephrectomy, were also compared by
immunohistochemistry and immunoblotting. The RCC1, RCC3
and RCC8 tissues shown in Figure 3 as typical examples were all
RCCs of the clear cell carcinoma type. Immunohistochemical
staining of the normal parts of all analysed kidneys showed strong
staining signals in distal tubules, but no staining was observed in
glomeruli and proximal tubules. In the tumour tissues, however,
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Figure 5 Expression level of Ksp-cadherin mRNA in RCC tissue and the
corresponding normal kidney tissues of four RCC patients. Real-time PCR
analysis reveals that Ksp-cadherin mRNA expression levels in RCC tissues is
4–23 times lower than in the surrounding normal kidney tissues. However,
analysing the end products of real-time PCR after 40 cycles by gel
electrophoresis, uniformly strong bands could be observed in normal and
tumour tissues of all four (RCC8, RCC9, RCC10, RCC13) analysed
patients.
Normal
Tumour
pt
dt
B
A
Figure 6 In situ detection of Ksp-cadherin mRNA in RCC-tissue and the
corresponding normal part of the affected kidney. Frozen sections of the
tumour and the normal kidney tissues of 13 patients were hybridised with
the
35S-labelled cadherin-16-specific antisense RNA probe. Clear signals
were only obtained in distal tubular epithelial cells (dt) of the normal
kidneys (A), whereas signal intensity in proximal tubules (A; pt) and tumour
cells (B) was not significantly higher than the background.
Ksp-cadherin in RCC
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sno staining signals at all were detected (Figure 7A). These findings
were confirmed with lysates from tumour tissues and the normal,
unaffected parts of the kidneys by Western blot analyses. Here, a
band of 130kDa specific for Ksp-cadherin was only found in the
lanes loaded with lysates from normal kidneys (Figure 7B).
DISCUSSION
Ksp-cadherin is an organ-specific member of the cadherin family,
which in the human kidney is exclusively found on distal tubules
and collecting ducts. During development, Ksp-cadherin does not
seem to be involved in the early transition of mesenchymal cells
into epithelial cells of the nephron, but appears later in epithelial
cells of distal tubules. In RCC tissues and cell lines, the Ksp-
cadherin protein cannot be detected, although the mRNA of this
cadherin is clearly detectable, albeit at a decreased level, by RT–
PCR analysis in tumour cells. Thus, Ksp-cadherin seems to be a
further important piece in the puzzling, highly complex expression
pattern of the cadherin family in normal and diseased human
kidneys.
This first description of Ksp-cadherin expression in human
embryonic tissue is in accordance with data obtained in neonatal
rabbit kidneys (Thomson and Aronson, 1999), where a relatively
late expression of Ksp-cadherin during nephrogenesis has also
been observed. The relatively late appearance of Ksp-cadherin
during renal development is in contrast to the expression pattern
of other cadherins, such as cadherin-8, which can clearly be
detected at the 6th week of gestation (Blaschke et al, 2002). E-
cadherin, which colocalises with Ksp-cadherin in distal tubules of
the adult kidney, appears earlier during renal development,
directly after the mesenchymal–epithelial transition (Vestweber
et al, 1985). Thus, it could be speculated that E-cadherin is
involved in the initial stages of tubulogenesis, whereas Ksp-
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Figure 7 (A) Detection of Ksp-cadherin protein expression in RCC tissues and nonmalignantly transformed kidney tissues of the same RCC patients by
immunohistochemical staining (A) and Western blotting (B). Ksp-cadherin can be detected in distal tubules of the normal part of the kidney from patients 1,
3 and 8 (A, top panel), but in none of the RCC tissues (A, bottom panel). (B) The Western blot analysis with lysates from renal tumour tissue and normal
parts of the affected kidneys from patients 1, 3 and 8 showed strong specific signals only in the lanes loaded with the lysates from normal kidneys.
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scadherin might play a role in stabilisation of terminally
differentiated renal distal tubular cells.
In the nephrons of the adult human kidney, Ksp-cadherin
expression was observed to be restricted to distal tubules. This was
shown by colocalisation with a lectin specifically binding to distal
tubules. However, there is an obvious discrepancy between our
data and the results obtained by Thomson and Aronson (1999),
who reported that Ksp-cadherin can be found on proximal as well
as on distal tubules. This discrepancy might be explained by the
use of two different antibodies, anti-human Ksp-cadherin anti-
bodies (our present study) and anti-rabbit Ksp-cadherin anti-
bodies (Thomson and Aronson, 1999). The restricted expression
pattern of Ksp-cadherin on human renal distal tubules, however,
seems to be important in view of the fact that most RCC develop
from proximal tubules.
In RCC tissues and cell lines, Ksp-cadherin mRNA could be
easily detected by classical end point RT–PCR analysis. Real-time
PCR, however, revealed that Ksp-cadherin mRNA can be detected
in RCC tumours, but the level of mRNA in the tumour tissues is
drastically reduced in comparison to normal tissues. This finding
was confirmed by in situ hybridisation of Ksp-cadherin mRNA in
RCC tissues, where no significant increase above background
levels could be was observed. Reverse transcriptase–PCR is a very
sensitive and highly specific method, which amplifies even tiny
amounts of Ksp-cadherin mRNA in the tumour tissues which
cannot be unambiguously detected by in situ hybridisation. Thus,
the observed, but reduced transcription of the Ksp-cadherin
mRNA in RCC tumour tissues and cell lines by RT–PCR without
an obvious translation into the Ksp-cadherin protein can be
explained in several ways. The most likely explanation is that the
amount of Ksp-cadherin mRNA in the tumour tissue is too low to
generate enough Ksp-cadherin protein to be detected immuno-
chemically. Secondly, since we have amplified only a part of exon
14 and exon 15 of Ksp-cadherin mRNA, we cannot exclude that a
frameshift mutation might have occurred in the RCC cells which
cannot be recognised by the RT–PCR analysis. However, since
different RCC cell lines and native tumour tissues were analysed,
this possibility seems to be unlikely. A third possibility, that the
protein is transcribed but rapidly degraded, is also very unlikely
since (I) no degradation products were observed by Western
blotting and (II) incubation of RCC cell lines with the proteasome
inhibitor ALLN did not lead to detectable protein bands by
immunoblotting. At the moment we can only conclude that RCC
tumour cells express small amounts of Ksp-cadherin mRNA, but
no or very low level of detectable protein seems to be translated.
However, this knowledge could be used to detect circulating RCC
tumour cells by a nested RT–PCR analysis in the periphery of RCC
patients, since a kidney cell-specific promoter is responsible for
the transcription of Ksp-cadherin mRNA.
Kidney-specific cadherin, as well as E-cadherin, is expressed on
distal tubular cells, but most of the RCC cells originate from
proximal tubular cells. Therefore, lack of Ksp-cadherin protein
expression in RCC tumour tissues seems to be in accordance with
the origin of the tumours. However, expression of E-cadherin on
RCC tumour cells, which due to the origin must be regarded as an
aberrant expression pattern, can be correlated with tumour stages
but not with survival rates (Katagiri et al, 1995; Shimazui et al,
1997). It will be a challenge for the near future to determine in a
larger cohort of patients whether the expression of Ksp-cadherin
mRNA can also be correlated with different tumour stages or
survival rates.
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